Table 1.
Descriptive analysis of immune response after COVAXIN and paired analysis of antibody titer at first and third assessment after full vaccination.
| Antibody Type | 30 days after the second dose of COVAXIN | 90 days after the second dose of COVAXIN | p-value derived from Wilcoxon Rank test |
|---|---|---|---|
| Anti-SARS-CoV-2 Antibody, Rapid test | N = 151 | N = 148 | <0.01 |
| Negative | 82(54.3%) | 97 (65.5%) | |
| Positive | 69 (45.7%) | 51 (34.5%) | |
| Anti-Nucleocapsid Antibody | N = 152 | N = 146 | |
| Median (IQR; 25%-75%) | 2.5 (0.9–4.6) | 1.3 (0.5–3.1) | <0.001 |
| < 1.1 | 43 (28.3%) | 70 (47.9%) | |
| 1.1< Antibody <3.0 | 49 (32.2%) | 36 (24.7%) | |
| 3.0< Antibody<10 | 55 (36.2%) | 36 (24.7%) | |
| >10 | 5(3.3%) | 4 (2.7%) | |
| Anti-Spike Antibody | N = 152 | N = 148 | |
| Median (IQR; 25%-75%) | 3.1 (1.6–5.1) | 2.6 (1.1–4.7) | <0.001 |
| ≤1.1 | 23 (15.1%) | 36 (24.3%) | |
| 1.1<Antibody≤3.0 | 46 (30.3%) | 45 (30.4%) | |
| 3.0<Antibody≤10 | 82(53.9%) | 59 (39.9%) | |
| >10 | 1 (0.7%) | 8 (5.4%) | |
| Neutralizing Antibody | N = 152 | N = 147 | |
| Median (IQR; 25%-75%) | 25.4 (13.1–31.9) | 12.2 (4.6–24.4) | <0.001 |
| < 2.5 | 11 (7.2) | 29 (22.4%) | |
| 2.5<Antibody<10 | 14 (9.2) | 33 (22.4) | |
| >10 | 127 (83.6) | 85 (57.8%) |